Search Results
Your search for ,had matches 18497 pages
Showing 751 - 800NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations
In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al found that afatinib prolonged progression-free survival vs platinum-based chemotherapy in patients who had treatment-naive nonsquamous non–small cell lung cancer (NSCLC) with...
AI Model Estimates Biological Age and Predicts Survival in Patients With Cancer
FaceAge, a deep learning system, was developed and validated to estimate biological age from photographs of faces. In a study published in The Lancet Digital Health, FaceAge showed the ability to predict short-term outcomes in patients with cancer. The study demonstrated that FaceAge could...
Overall Survival Analysis in CodeBreaK 300: Sotorasib Plus Panitumumab vs Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer
As reported in the Journal of Clinical Oncology by Pietrantonio et al, overall survival analysis in the phase III CodeBreaK 300 trial showed numeric improvement with sotorasib/panitumumab vs investigator's choice of treatment in patients with chemorefractory KRAS G12C-mutant metastatic colorectal...
Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented ...
Cohort Study Shows Benefits of Bilateral Salpingo-Oophorectomy Without Increased Health Risks
Patients with a history of breast cancer who are carriers of BRCA1 and BRCA2 pathogenic variants benefit from undergoing bilateral salpingo-oophorectomy, the results of a retrospective cohort study published in The Lancet Oncology showed. Women who had their ovaries and fallopian tubes removed...
GLP-1 Receptor Agonists Could Show Anticancer Benefits Beyond Weight Loss
First-generation weight-loss drugs like liraglutide and exenatide could show anticancer benefits beyond weight loss, according to findings from a retrospective, observational study presented by Sagy et al at the European Congress on Obesity (ECO) 2025 and simultaneously published in...
Combination of Weight Gain, Age at Pregnancy Could Increase Breast Cancer Risk
Investigators have found that the risk of developing breast cancer could be nearly three times higher among women who experience notable weight gain after the age of 20 years and either give birth after age 30 or don’t have children compared with those who give birth before age 30 and whose weight...
CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer
In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor-infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Effects of Tumor-Infiltrating Clonal Hematopoiesis
In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of death or recurrence among patients with early-stage non–small cell lung cancer (NSCLC) and poorer overall survival among...
Early-Onset Breast, Colorectal, Endometrial, Pancreatic, and Kidney Cancers on the Rise
Recent studies have shown increasing rates of early-onset cancers, often defined as cancers occurring in people younger than age 50, especially colorectal, pancreatic, female breast, and uterine cancers, and younger birth cohorts seem to have a higher risk of some cancer types compared with older...
Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn
The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to...
How Could So Many Physicians Have Failed Me?
The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...
Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved...
Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD
Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers. The pinnacle of ...
Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026
The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director of Clinical Cancer Research and the ...
Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research
The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant fundamental contributions to cancer...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
2024 Annual Report to the Nation on the Status of Cancer Finds Mortality Rates Continue to Decline
Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, which was published by Recinda L. Sherman, MPH, PhD, ODS-C, of the North American Association of Central...
Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer
The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed monoclonal antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib in the first-line ...
Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other CAR T-cell therapies have been FDA approved to treat adults with blood cancers, including...
Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers
For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph node techniques. At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Study Shows Disparities in Diagnosing Endometrial Cancer in Women With Postmenopausal Bleeding
Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial differences in transvaginal ultrasound efficacy combined with timely receipt of indicated endometrial...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Symptoms Preceding Unplanned Acute Care in Patients With Cancer
In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study Details The study involved data from all unplanned acute care encounters (emergency department visits and...
HIV-Related Structural Barriers in Cancer Care
Patients with human immunodeficiency virus (HIV) are less likely to receive potentially life-saving cancer treatment if they reside in communities with lower income levels and educational attainment, according to a recent study published by Islam et al in Cancer. Study Methods and Results...
Influence of ACA on Breast Reconstruction Disparities
Despite steady increases in the rates of immediate postmastectomy breast reconstruction, racial disparities in receipt of the procedure have persisted in the years since the implementation of the Affordable Care Act (ACA), according to a recent study published by Schafer et al in Plastic and...
Five Major Advances in Radiotherapy for Anal and Rectal Cancer Presented at ESTRO 2025
Five pivotal studies presented at ESTRO 2025 showcase how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations offer safer, more effective, and organ-preserving...
New Treatment Approach Could Enhance Care for Aggressive Relapsed/Refractory T- and NK-Cell Lymphomas
Investigators have uncovered how a specific sequence of cancer therapies could improve outcomes among patients with relapsed/refractory mature T- and natural killer (NK)-cell lymphomas, according to a recent study published by Sorial et al in the British Journal of Haematology. Background...
Cancer Briefs From Digestive Disease Week 2025
Cancer-related studies were among the nearly 6,000 abstracts presented at Digestive Disease Week® (DDW) 2025, including research on artificial intelligence (AI) in patient communication, polyp detection, and colonoscopy prep. Use of AI in Patient Communication AI outperformed physicians in...
Early-Stage Stomach Cancer Diagnoses on the Rise
Stomach cancers are increasingly being diagnosed at less advanced, more treatable stages—a shift that marks major progress in detecting one of the deadliest forms of cancer, according to a study presented at Digestive Disease Week® (DDW) 2025 (Abstract Sa1374). “These trends suggest that...
Anal Cancer Rates Rising Most Among Older White and Hispanic Women
Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study presented at Digestive Disease Week 2025 (Abstract 76) found. According to the investigators, this shift challenges assumptions about high-risk...
Association for Clinical Oncology: Proposed Changes to Federal Health Agencies Threaten Future Cancer Research Advancements
The Association for Clinical Oncology is carefully reviewing the Administration’s Fiscal Year 2026 (FY 2026) budget proposal, which was released on May 2 and contains significant cuts to federal health agencies under the Department of Health and Human Services (HHS), notably a 40% cut to the...
AML: MRD Testing Led to Survival Benefits in Subset of Patients
Sequential molecular measurable residual disease (MRD) testing and monitoring led to a survival benefit among younger patients with acute myeloid leukemia (AML) and NPM1 and FLT3-ITD mutations, according to the results of a study published in The Lancet Haematology. Patients with both mutations...
Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC
In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that fluorodeoxyglucose (FDG)-PET–guided heterogeneously dose-escalated radiotherapy was not associated with greater 6-month toxicity vs standard radiotherapy in...
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates. Study Details In the...
Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology. The 5-year mortality rate in patients with a...
AACR 2025: Novel CAR T-Cell Therapy Induces Response in Patients With Advanced Thyroid Cancers
A novel chimeric antigen receptor (CAR) T-cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer. Results from a small, first-in-human phase I trial were presented at the ...
DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths
A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halved deaths, and brought racial differences in outcomes to nearly zero, according to a study that will ...
DDW 2025: Genetic Mutations Linked to Worse Stomach Cancer Outcomes
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
AACR 2025: Molecularly Selected, Tumor-Agnostic Phase II Trial Focuses on Combination Therapy
According to the results of a molecularly matched, tumor-agnostic phase II trial, the combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab demonstrated antitumor activity with no new safety signals, particularly in patients with BRCA1/2 mutations. Data from this...
AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial results were presented by Anisha B. Patel, MD, Associate Professor of Dermatology, Deputy Chair of...
AACR 2025: Trends in Breast Cancer Incidence for Women Between the Ages of 20 and 49
Breast cancer deaths among women between the ages of 20 and 49 declined significantly across all breast cancer subtypes and racial/ethnic groups from 2010 to 2020, with marked declines starting after 2016, according to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER)...
AACR 2025: AI-Driven Model For Identifying Cancer Cachexia
Use of a multimodal deep learning–based model led to more accurate and earlier identifications of cancer cachexia than standard clinical and radiological observations, according to findings presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 1143)....
AACR 2025: Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies
Although next-generation sequencing to assist decision-making for genomics-driven therapy in patients with advanced solid tumors has traditionally been conducted using tissue biopsy samples, recent data support the use of plasma-based circulating tumor DNA (ctDNA) for the genomic profiling of solid ...
AACR 2025: Novel Targeted Therapy Under Study in Selected Patients With Advanced Solid Tumors
The first-in-class covalent Werner helicase inhibitor (RO7589831) demonstrated early signals of efficacy as well as general tolerability in patients with advanced solid tumors harboring certain genetic defects, according to results from a phase I trial. Agents in this class target the DNA repair...
AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer
The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation, according to the preliminary results of the early-phase Beamion LUNG-1 trial. These findings were...
AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...
AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC
The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...
